Famed for its dominance in antiviral therapies for hepatitis C and HIV, Gilead is expected to soon extend its presence into hepatitis Delta, a less well known but far more severe form of hepatitis.
Its antiviral bulevirtide (aquired with MYR two years ago) is now under review at the US Food and Drug Administration for use in patients with compensated liver disease, and is already available in Europe as Hepcludex
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?